NMN (Nicotinamide Mononucleotide)

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

NMN (Nicotinamide Mononucleotide)

An NAD+ precursor studied in an early human dose-finding trial.

Evidence category: Clinical study. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

NMN, or nicotinamide mononucleotide, is a naturally occurring compound and a direct precursor in the body's production of NAD+, a molecule central to cellular energy metabolism. Interest in NMN grew out of animal aging research, and it has since moved into a small but growing number of human trials examining safety and its effects on NAD+ levels, metabolism, and physical performance. Long-term human outcome data, including any effect on aging itself or chronic disease risk, remain limited.

Benefits reported in the imported source

• Well-designed randomized trials show NMN reliably raises blood NAD+ levels in healthy adults
• Short-term trials report good tolerability with no serious adverse events
• Early data point to possible benefits for physical endurance measures

Risks and limits

• Long-term safety and effectiveness beyond a few months of use have not been studied in humans
• Much of the foundational evidence for anti-aging effects comes from animal models and has not been confirmed in people
• Regulatory status is unsettled and commercial product purity varies widely

Source bottom line: NMN reliably raises NAD+ levels in short human trials and appears well tolerated, but the leap from that biomarker change to a meaningful long-term health benefit remains unproven in people.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

No half-life recorded in this source snapshot. No value has been inferred.

Source references

• The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults - PubMed